Scopus

Permanent URI for this collectionhttps://hdl.handle.net/11452/20668

Browse

Browsing by BUU Author "Açıkgöz, Ebru"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Correlates of visceral and subcutaneous fat thickness in non-diabetic obese and morbidly obese patients
    (Carbone Editore, 2017) Şeker, İsmail; Gül, Özen Öz; Pekgöz, Murat; Güllülü, Sümeyye; Cander, Soner; Tutuncu, Ahmet; Sağ, Saim; Açıkgöz, Ebru; Sarandol, Emre; Ersoy, Canan; Uludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı/İç Hastalıkları Anabilim Dalı.; Uludağ Üniversitesi/Fen-Edebiyat Fakültesi/Kardiyoloji Anabilim Dalı.; 0000-0002-2593-7196; 0000-0001-8404-8252; AAH-8861-2021; ABE-1716-2020; AAW-9185-2020; AAI-1005-2021; 26040787100; 36010142900; 57204660708; 25027068600; 7004229025; 12140008100; 56328183700; 55943324800; 6701485882
    Background: To determine the correlates of visceral and subcutaneous fat thickness in non-diabetic obese and morbidly obese patients Methods: A total of 31 obese female outpatients composed of morbidly obese (n=16, BMI of >= 40kg/m(2)) and obese (n=15, BMI of 30-39.9kg/m(2)) patients were included in the present study. Data on age, anthropometrics, blood biochemistry, HOMA-IR, carotid intima-media thickness (CIMT) were recorded in each subject as were plasma resistin (mu g/L) and visfatin (mu g/ml) levels, epicardial, subcutaneous and abdominal fat thickness (mm). Correlates of visceral and subcutaneous fat thickness were determined via linear regression models with inclusion of severity of obesity, insulin resistance, plasma resistin and visfatin levels and CIMT as variables. Results: Epicardial fat thickness (mm) was 3.1(1.0-10.20) and 8.8(2.60-13.0), CIMT (mm) was 5.8(4.7-8.9) and 5.9(4-8.6), abdominal fat thickness (mm) was 10.8(7.8-16.1) and 13.2(8.7-16.5), subcutaneous fat thickness(mm) was 43.8(28.4-62.9) and 57.4(39.5-72.7), plasma resistin levels (mu g/L) were 8.5(4.7-38.1) and 10.8(0.7-26.4) and plasma visfatin levels (mu g/ml) were 55.5(5.1-209.5) and 78.2(4.7-228) in obese and morbidly obese patients, respectively. Linear regression analysis revealed that being morbidly obese was likely to increase epicardial fat thickness by 4.33mm(p=0.004) compared with obesity, while for each 1 unit increase in HOMA levels, subcutaneous fat thickness was likely to decrease by 1.16mm(p=0.009). Conclusion: In conclusion, our findings revealed that neither plasma levels for resistin and visfatin nor CIMT correlated with visceral or subcutaneous fat thickness in non-diabetic obese females, while increase in subcutaneous and epicardial fat thickness values were noted with decrease in HOMA-IR and the presence of morbid obesity, respectively.
  • No Thumbnail Available
    Publication
    The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure
    (Taylor & Francis, 2015-05-12) Beşli, Feyzullah; Güllülü, Sümeyye; Sağ, Saim; Keçebaş, Mesut; Açıkgöz, Ebru; Sarandöl, Emre; Aydınlar, Ali; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.; 0000-0002-8974-8837; 0000-0001-8404-8252; 0000-0002-2593-7196; AAI-6632-2021; AAW-9185-2020; ABE-1716-2020; 35767335000; 57204660708; 12140008100; 36198369900; 56328183700; 55943324800; 6603131517
    Objectives Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) appears to be involved in atherosclerotic plaque vulnerability and rupture. In this study, we aimed to evaluate the utility of serum LOX-1 levels in the diagnosis and assessment of left ventricular systolic HF and LOX-1's relationship with serum pro-brain natriuretic peptide (NT-proBNP). Design and settings This was a cross-sectional study of all eligible patients admitted to the department of cardiology of the University Hospital between July 2011 and April 2012. Methods Fifty-five patients with a diagnosis of systolic heart failure and 25 patients without systolic HF were enrolled in this study. Serum C-reactive protein, NT-proBNP, and LOX-1 were studied. Results Serum LOX-1 and NT-proBNP levels were significantly higher in the heart failure group and showed a positive correlation with NT-proBNP and negative correlations with left ventricular ejection fraction (EF). In addition, LOX-1 levels in patients with ischaemic cardiomyopathy were significantly higher, while they were similar in patients with dilated cardiomyopathy compared to control subjects. Conclusion Our study demonstrates the utility of the serum LOX-1 levels in the diagnosis of left ventricular systolic heart failure. LOX-1 may have a place in the diagnosis of heart failure, in particular in patients with ischaemic cardiomyopathy.